Results 21 to 30 of about 44,151 (306)

Hepatoprotective Role of Carvedilol against Ischemic Hepatitis Associated with Acute Heart Failure via Targeting miRNA-17 and Mitochondrial Dynamics-Related Proteins: An In Vivo and In Silico Study

Pharmaceuticals, 2022
Acute heart failure (AHF) is one of the most common diseases in old age that can lead to mortality. Systemic hypoperfusion is associated with hepatic ischemia–reperfusion injury, which may be irreversible. Ischemic hepatitis due to AHF has been linked to
D. Mohamed, S. Ezzat, W. Elayat, Omnyah A. El-Kharashi, H. F. A. El-Kareem, H. A. Nahas, Basel A. Abdel-Wahab, S. Alshawwa, A. Saleh, Yosra A. Helmy, Eman Y Khairy, Essa M. Saied   +11 more
semanticscholar   +1 more source

Association between heart failure quality of care and mortality: a population‐based cohort study using nationwide registries

European Journal of Heart Failure, Volume 24, Issue 11, Page 2066-2077, November 2022., 2022
Hospital performance and outcomes according to the 2021 European Society of Cardiology (ESC) quality indicators for heart failure (HF). ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; CRT, cardiac resynchronization therapy; ECG, electrocardiogram; HFrEF, heart failure ...
Gorav Batra, Suleman Aktaa, Lina Benson, Ulf Dahlström, Camilla Hage, Gianluigi Savarese, Peter Vasko, Chris P. Gale, Lars H. Lund   +8 more
wiley   +1 more source

How Carvedilol activates β2-adrenoceptors

Nature Communications, 2022
Carvedilol is among the most effective β-blockers for improving survival after myocardial infarction. Yet the mechanisms by which carvedilol achieves this superior clinical profile are still unclear.
Tobias Benkel, M. Zimmermann, J. Zeiner, Sergi Bravo, Nicole Merten, Victor Jun Yu Lim, E. Matthees, J. Drube, E. Miess-Tanneberg, D. Malan, M. Szpakowska, Stefania Monteleone, J. Grimes, Z. Kőszegi, Y. Lanoiselée, S. O’Brien, Nikoleta Pavlaki, Nadine Dobberstein, A. Inoue, V. Nikolaev, D. Calebiro, A. Chevigné, P. Sasse, S. Schulz, C. Hoffmann, P. Kolb, M. Waldhoer, Katharina Simon, J. Gomeza, E. Kostenis   +29 more
semanticscholar   +1 more source

In silico drug repurposing carvedilol and its metabolites against SARS-CoV-2 infection using molecular docking and molecular dynamic simulation approaches

Scientific Reports, 2023
The pandemic of coronavirus disease 2019 (COVID-19) caused by the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a significant impact on the economy and public health worldwide.
Chunye Zhang, Jiazheng Liu, Yuxiang Sui, Shuai Liu, Ming Yang   +4 more
doaj   +1 more source

Mechanism of carvedilol induced action potential and calcium alternans

Channels, 2022
Carvedilol is a nonspecific β-blocker clinically used for the treatment of cardiovascular diseases but has also been shown to have profound effects on excitation-contraction coupling and Ca signaling at the cellular level. We investigate the mechanism by
Elizabeth Martinez-Hernandez, Giedrius Kanaporis, Lothar A. Blatter   +2 more
doaj   +1 more source

Platelet-Membrane-Encapsulated Carvedilol with Improved Targeting Ability for Relieving Myocardial Ischemia–Reperfusion Injury

Membranes, 2022
In recent years, cell membrane drug delivery systems have received increasing attention. However, drug-loaded membrane delivery systems targeting therapy in myocardial ischemia–reperfusion injury (MIRI) have been relatively rarely studied. The purpose of
Tingting Zhou, Xuechao Yang, Tianyi Wang, Mingming Xu, Zhanghao Huang, Run-Jie Yu, Y. Jiang, Youlang Zhou, Jiahai Shi   +8 more
semanticscholar   +1 more source

The Adrenergic Receptor Antagonist Carvedilol Elicits Anti-Tumor Responses in Uveal Melanoma 3D Tumor Spheroids and May Serve as Co-Adjuvant Therapy with Radiation

Cancers, 2022
Simple Summary Decades of research efforts aiming to identify a new therapy for reducing mortality rates in metastatic uveal melanoma (UM) have not been successful.
Lina S. Farhoumand, M. Fiorentzis, M. M. Kraemer, A. Sak, M. Stuschke, T. Rassaf, U. Hendgen-Cotta, N. Bechrakis, U. Berchner‐Pfannschmidt   +8 more
semanticscholar   +1 more source

Formulation and Characterization of Acetazolamide/Carvedilol Niosomal Gel for Glaucoma Treatment: In Vitro, and In Vivo Study

Pharmaceutics, 2021
Acetazolamide (ACZ) is a diuretic used in glaucoma treatment; it has many side effects. Carvedilol (CAR) is a non-cardioselective beta-blocker used in the treatment of elevated intraocular pressure; it is subjected to the first-pass metabolism and causes
Rehab Abdelmonem, S. Elhabal, N. S. Abdelmalak, M. EL-NABARAWI, M. Teaima   +4 more
semanticscholar   +1 more source

Fusion of the β2‐adrenergic receptor with either Gαs or βarrestin‐2 produces constitutive signaling by each pathway and induces gain‐of‐function in BEAS‐2B cells

FASEB BioAdvances, Volume 4, Issue 12, Page 758-774, December 2022., 2022
Abstract The β2AR is a prototypical G protein‐coupled receptor (GPCR) known to orchestrate different cellular responses by the stimulation of specific signaling pathways. The best‐established signaling pathways for the β2AR are the canonical Gs pathway and the alternative β arrestin 2 (βarr2) pathway.
Emilio Y. Lucero‐Garcia Rojas, Arfaxad Reyes‐Alcaraz, Kehe Ruan, Bradley K. McConnell, Richard A. Bond   +4 more
wiley   +1 more source

β-Arrestin–Biased Allosteric Modulator Potentiates Carvedilol-Stimulated β Adrenergic Receptor Cardioprotection

Molecular Pharmacology, 2021
β1 adrenergic receptors (β1ARs) are central regulators of cardiac function and a drug target for cardiac disease. As a member of the G protein–coupled receptor family, β1ARs activate cellular signaling by primarily coupling to Gs proteins to activate ...
Jialu Wang, Biswaranjan Pani, Ilhan Gokhan, Xinyu Xiong, Alem W. Kahsai, Haoran Jiang, Seungkirl Ahn, R. Lefkowitz, H. Rockman   +8 more
semanticscholar   +1 more source